Welcome to our dedicated page for CNS Pharmaceuticals SEC filings (Ticker: CNSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CNS Pharmaceuticals, Inc. (CNSP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CNS Pharmaceuticals is a clinical-stage biopharmaceutical company whose common stock trades on The Nasdaq Stock Market LLC under the symbol CNSP, as noted in its current reports on Form 8-K.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information on CNS Pharmaceuticals’ financial condition, risk factors, and discussion of its clinical-stage pipeline of anti-cancer drug candidates for brain and central nervous system tumors. These periodic reports complement the company’s press releases describing its lead candidate TPI 287, an abeotaxane with initial clinical data suggesting potential to cross the blood-brain barrier and treat CNS tumors.
The filings feed also includes current reports on Form 8-K that document material events. Recent 8-K filings describe a leadership transition in which the company entered into an employment agreement with Rami Levin to serve as Chief Executive Officer and President, the resignation and severance arrangements for former CEO John Climaco, and stockholder-approved changes to the company’s capital structure, including amendments to its articles of incorporation and 2020 Equity Plan.
Investors can also use this page to track proxy materials such as the definitive proxy statement on Schedule 14A, which outlines proposals presented at the annual meeting, including election of directors, auditor ratification, advisory votes on executive compensation, and increases in authorized share capital. Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping users quickly understand complex filings, from governance decisions to equity plan amendments, while retaining the ability to read the full original SEC text.
CNS Pharmaceuticals, Inc. entered into a private placement with institutional investors, selling 650,000 shares of common stock at $2.30 per share and issuing pre-funded warrants for 9,143,479 shares at $2.299 per warrant. Gross proceeds are expected to be approximately $22.5 million before fees.
The pre-funded warrants are exercisable immediately at $0.001 per share, subject to a 4.99% or 9.99% beneficial ownership cap, and remain outstanding until fully exercised. The company plans to use net proceeds to identify, acquire, and advance new assets and for working capital and general corporate purposes.
CNS Pharmaceuticals agreed to register the resale of the shares and underlying warrant shares and accepted restrictions on additional equity sales and variable rate transactions for specified periods. The company also announced the resignation of director Jerzy (George) Gumulka and the appointment of life sciences executive Michal Fisher as an independent board member.
CNS Pharmaceuticals, Inc. filed an amended annual report to add updated Part III information on directors, executive compensation, ownership and auditor matters for the year ended December 31, 2025. The filing does not change prior financial statements and should be read together with the original Form 10-K.
The company reports aggregate market value of voting equity held by non-affiliates of $8.78 million and 811,449 common shares outstanding as of April 27, 2026. It details a leadership transition from former CEO John Climaco to new CEO Rami Levin and provides 2025 compensation data, board committee composition, equity plan usage and auditor fee disclosures.
CNS Pharmaceuticals, Inc. ownership disclosure: Ikarian Capital, LLC and Neil Shahrestani report shared beneficial ownership of 45,830 shares of Common Stock, representing 5.7% of the class. The stake is held via Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts, with 811,449 shares outstanding as of March 31, 2026 as disclosed in the issuer's Form 10-K.
The filing states that Ikarian Capital exercises investment discretion for the Fund and managed accounts and that Mr. Shahrestani may be deemed to beneficially own the securities indirectly; the Fund and the Managed Accounts disclaim cross-beneficial ownership.
CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company pivoting from a historical focus on glioblastoma to building an in-licensed pipeline in neurology and oncology. A new CEO took over on January 1, 2026, followed by a rebuilt executive team effective March 2, 2026, and a new growth strategy announced on March 11, 2026.
The company plans to out-license its legacy GBM assets TPI 287 and Berubicin after Berubicin’s Phase 2 trial failed to show superiority over lomustine in overall survival. As of December 31, 2025, CNS held cash of about $7,201,000 and working capital of roughly $4,002,000, expects its cash to fund operations into the third quarter of 2026, and reported an accumulated deficit of $100,275,268.
The independent auditor expressed substantial doubt about the company’s ability to continue as a going concern. Non‑affiliate voting equity was valued at approximately $5.0 million as of the last business day of the most recently completed second fiscal quarter, and 811,449 common shares were outstanding as of March 31, 2026. CNS had eight full‑time employees and will require significant additional capital to execute its licensing-focused strategy and continue operations.
CNS Pharmaceuticals, Inc. furnished an investor presentation outlining a new corporate growth strategy led by a recently installed executive team. The company is pivoting to focus on high-value neurology and oncology markets, emphasizing data-driven, capital-efficient development and targeting assets with strong biological rationale and near-term catalysts.
The strategy includes a formal global search for differentiated preclinical and clinical-stage programs, while positioning legacy glioblastoma multiforme programs such as Berubicin and TPI 287 for potential out-licensing. Management highlights neurology and oncology as large, growing therapeutic areas with significant unmet needs and active deal flow.
Faulkner Eric reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals granted Chief Technology Officer Eric Faulkner 9,500 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one share of common stock. The award was issued in connection with his employment.
The RSUs vest over time: 25% after six months, another 25% after twelve months, and the remaining 50% in twelve quarterly installments thereafter, provided he remains employed on each vesting date. This is a stock-based compensation grant rather than an open-market share purchase.
CNS Pharmaceuticals, Inc. reported that Eric Faulkner, the company’s Chief Technology Officer, has filed an initial insider ownership report on Form 3. This filing establishes his status as an officer subject to insider reporting rules but does not list any share transactions or holdings in the excerpt provided.
O'Loughlin Steve reported acquisition or exercise transactions in this Form 4 filing.
CNS Pharmaceuticals, Inc. reported that Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units on March 2, 2026. Each restricted stock unit represents a contingent right to receive one share of the company’s common stock, issued in connection with his employment.
The award vests over time: 25% on the six-month anniversary of the grant date, another 25% on the twelve-month anniversary, and the remaining 50% in twelve quarterly installments thereafter, subject to his continued employment on each vesting date. Following this grant, he holds 9,500 restricted stock units directly.
CNS Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Steve O'Loughlin. This Form 3 confirms his status as an officer who is subject to insider reporting rules, but does not list any specific stock transactions or changes in ownership.
CNS Pharmaceuticals has appointed Dr. Lynne Kelley as Chief Medical Officer effective March 2, 2026. Her employment agreement includes a base salary of $450,000, an annual bonus target equal to 40% of base salary, and eligibility for future equity grants determined by the board’s Compensation Committee.
Dr. Kelley will also receive an initial grant of 9,500 restricted stock units, vesting 25% after six months, 25% after twelve months, and the remaining 50% in twelve quarterly installments, subject to continued employment. If she is terminated without cause or resigns for good reason, she is entitled to six months of base salary, a pro-rated target bonus, and accelerated vesting of all unvested equity, subject to a release of claims and covenant compliance.
The company also entered into a separation and severance agreement with former Chief Medical Officer Dr. Sandra Silberman, providing severance equal to three months of her current annualized base salary, paid in three monthly installments.